nodes	percent_of_prediction	percent_of_DWPC	metapath
Degarelix—GNRHR—Peptide GPCRs—CXCR1—melanoma	0.0109	0.0314	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—MC1R—melanoma	0.0107	0.031	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—CCR7—melanoma	0.0103	0.0297	CbGpPWpGaD
Degarelix—GNRHR—GPCRs, Other—CXCR1—melanoma	0.00921	0.0266	CbGpPWpGaD
Degarelix—GNRHR—GPCRs, Other—GRM1—melanoma	0.0087	0.0252	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—CXCR2—melanoma	0.0085	0.0246	CbGpPWpGaD
Degarelix—GNRHR—GPCRs, Other—CXCR2—melanoma	0.00721	0.0208	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—PLCB4—melanoma	0.00705	0.0204	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—EDNRB—melanoma	0.007	0.0202	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PLCB4—melanoma	0.00631	0.0182	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—CXCR4—melanoma	0.00622	0.018	CbGpPWpGaD
Degarelix—GNRHR—GPCRs, Other—F2R—melanoma	0.00613	0.0177	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—F2RL1—melanoma	0.006	0.0173	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—F2RL1—melanoma	0.00536	0.0155	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—KISS1—melanoma	0.00534	0.0155	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—GRM1—melanoma	0.00489	0.0141	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—melanoma	0.00478	0.0138	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—TAS2R60—melanoma	0.00469	0.0136	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL1—melanoma	0.00467	0.0135	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—melanoma	0.00437	0.0126	CbGpPWpGaD
Degarelix—Alopecia—Vemurafenib—melanoma	0.00431	0.00659	CcSEcCtD
Degarelix—Mental disability—Temozolomide—melanoma	0.00431	0.00659	CcSEcCtD
Degarelix—Diabetes mellitus—Carmustine—melanoma	0.00429	0.00655	CcSEcCtD
Degarelix—Malnutrition—Vemurafenib—melanoma	0.00425	0.00649	CcSEcCtD
Degarelix—Erythema—Vemurafenib—melanoma	0.00425	0.00649	CcSEcCtD
Degarelix—Swelling—Carmustine—melanoma	0.00423	0.00646	CcSEcCtD
Degarelix—Blood alkaline phosphatase increased—Temozolomide—melanoma	0.00414	0.00633	CcSEcCtD
Degarelix—Back pain—Vemurafenib—melanoma	0.00411	0.00628	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—F2RL1—melanoma	0.00397	0.0115	CbGpPWpGaD
Degarelix—Hot flush—Temozolomide—melanoma	0.00385	0.00589	CcSEcCtD
Degarelix—Menopausal symptoms—Temozolomide—melanoma	0.00382	0.00584	CcSEcCtD
Degarelix—Bone disorder—Docetaxel—melanoma	0.00366	0.00559	CcSEcCtD
Degarelix—Arthralgia—Vemurafenib—melanoma	0.00362	0.00553	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00359	0.00549	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—CXCL1—melanoma	0.00356	0.0103	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—KISS1—melanoma	0.00354	0.0102	CbGpPWpGaD
Degarelix—Blood bilirubin increased—Docetaxel—melanoma	0.00349	0.00534	CcSEcCtD
Degarelix—Anaphylactic shock—Vemurafenib—melanoma	0.00347	0.0053	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—F2R—melanoma	0.00344	0.00996	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR1—melanoma	0.00343	0.00991	CbGpPWpGaD
Degarelix—Inflammation—Docetaxel—melanoma	0.0034	0.0052	CcSEcCtD
Degarelix—Nervous system disorder—Vemurafenib—melanoma	0.0034	0.0052	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—MC1R—melanoma	0.00338	0.00976	CbGpPWpGaD
Degarelix—Skin disorder—Vemurafenib—melanoma	0.00337	0.00515	CcSEcCtD
Degarelix—Weight decreased—Bleomycin—melanoma	0.00334	0.00511	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—EDNRB—melanoma	0.00333	0.00965	CbGpPWpGaD
Degarelix—Phosphatase alkaline increased—Docetaxel—melanoma	0.0033	0.00505	CcSEcCtD
Degarelix—Muscular weakness—Carmustine—melanoma	0.00329	0.00503	CcSEcCtD
Degarelix—Injection site reaction—Docetaxel—melanoma	0.00328	0.00502	CcSEcCtD
Degarelix—Breast disorder—Temozolomide—melanoma	0.00326	0.00498	CcSEcCtD
Degarelix—Acute coronary syndrome—Bleomycin—melanoma	0.00325	0.00496	CcSEcCtD
Degarelix—Hypotension—Vemurafenib—melanoma	0.00324	0.00495	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCR7—melanoma	0.00324	0.00936	CbGpPWpGaD
Degarelix—Myocardial infarction—Bleomycin—melanoma	0.00323	0.00493	CcSEcCtD
Degarelix—Influenza like illness—Docetaxel—melanoma	0.00321	0.0049	CcSEcCtD
Degarelix—Muscular weakness—Temozolomide—melanoma	0.00318	0.00486	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00316	0.00483	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—GNA11—melanoma	0.00315	0.00911	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—F2R—melanoma	0.00308	0.00891	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—F2RL1—melanoma	0.00302	0.00874	CbGpPWpGaD
Degarelix—Decreased appetite—Vemurafenib—melanoma	0.00301	0.00461	CcSEcCtD
Degarelix—Gastrointestinal disorder—Vemurafenib—melanoma	0.00299	0.00457	CcSEcCtD
Degarelix—Fatigue—Vemurafenib—melanoma	0.00299	0.00457	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRB—melanoma	0.00298	0.00863	CbGpPWpGaD
Degarelix—Constipation—Vemurafenib—melanoma	0.00296	0.00453	CcSEcCtD
Degarelix—Hypoaesthesia—Bleomycin—melanoma	0.00294	0.0045	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—GNAQ—melanoma	0.00293	0.00847	CbGpPWpGaD
Degarelix—Dysuria—Temozolomide—melanoma	0.00291	0.00445	CcSEcCtD
Degarelix—Hyperglycaemia—Carmustine—melanoma	0.00291	0.00444	CcSEcCtD
Degarelix—Pollakiuria—Temozolomide—melanoma	0.00288	0.0044	CcSEcCtD
Degarelix—Erectile dysfunction—Temozolomide—melanoma	0.00287	0.00439	CcSEcCtD
Degarelix—Depression—Carmustine—melanoma	0.00287	0.00438	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—GRM3—melanoma	0.00284	0.00822	CbGpPWpGaD
Degarelix—Weight increased—Temozolomide—melanoma	0.00284	0.00433	CcSEcCtD
Degarelix—Renal failure—Carmustine—melanoma	0.00283	0.00432	CcSEcCtD
Degarelix—Weight decreased—Temozolomide—melanoma	0.00282	0.00431	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—melanoma	0.00282	0.00815	CbGpPWpGaD
Degarelix—Hyperglycaemia—Temozolomide—melanoma	0.00281	0.0043	CcSEcCtD
Degarelix—Urinary tract infection—Carmustine—melanoma	0.00279	0.00427	CcSEcCtD
Degarelix—Depression—Temozolomide—melanoma	0.00277	0.00423	CcSEcCtD
Degarelix—Blood alkaline phosphatase increased—Docetaxel—melanoma	0.00276	0.00421	CcSEcCtD
Degarelix—Body temperature increased—Vemurafenib—melanoma	0.00274	0.00419	CcSEcCtD
Degarelix—Swelling—Docetaxel—melanoma	0.00272	0.00415	CcSEcCtD
Degarelix—Urinary tract infection—Temozolomide—melanoma	0.0027	0.00413	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—KISS1—melanoma	0.00269	0.00779	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR2—melanoma	0.00268	0.00776	CbGpPWpGaD
Degarelix—Chills—Bleomycin—melanoma	0.00265	0.00405	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—TAS2R60—melanoma	0.00265	0.00767	CbGpPWpGaD
Degarelix—Hepatobiliary disease—Temozolomide—melanoma	0.00263	0.00402	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—melanoma	0.00262	0.00757	CbGpPWpGaD
Degarelix—Alopecia—Bleomycin—melanoma	0.00261	0.00399	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—CXCR1—melanoma	0.00261	0.00755	CbGpPWpGaD
Degarelix—Erythema—Bleomycin—melanoma	0.00257	0.00393	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—MC1R—melanoma	0.00257	0.00744	CbGpPWpGaD
Degarelix—Hypoaesthesia—Carmustine—melanoma	0.00257	0.00392	CcSEcCtD
Degarelix—Hot flush—Docetaxel—melanoma	0.00256	0.00392	CcSEcCtD
Degarelix—Hypersensitivity—Vemurafenib—melanoma	0.00255	0.0039	CcSEcCtD
Degarelix—Oedema peripheral—Carmustine—melanoma	0.00254	0.00389	CcSEcCtD
Degarelix—Menopausal symptoms—Docetaxel—melanoma	0.00254	0.00388	CcSEcCtD
Degarelix—Atrial fibrillation—Docetaxel—melanoma	0.00253	0.00387	CcSEcCtD
Degarelix—Renal impairment—Docetaxel—melanoma	0.00252	0.00385	CcSEcCtD
Degarelix—Asthenia—Vemurafenib—melanoma	0.00249	0.0038	CcSEcCtD
Degarelix—Hypoaesthesia—Temozolomide—melanoma	0.00248	0.00379	CcSEcCtD
Degarelix—Chills—Dactinomycin—melanoma	0.00247	0.00378	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—CCR7—melanoma	0.00246	0.00713	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—GRM1—melanoma	0.00246	0.00713	CbGpPWpGaD
Degarelix—Urinary tract disorder—Temozolomide—melanoma	0.00246	0.00376	CcSEcCtD
Degarelix—Oedema peripheral—Temozolomide—melanoma	0.00246	0.00375	CcSEcCtD
Degarelix—Cardiac failure—Docetaxel—melanoma	0.00246	0.00375	CcSEcCtD
Degarelix—Pruritus—Vemurafenib—melanoma	0.00245	0.00375	CcSEcCtD
Degarelix—Urethral disorder—Temozolomide—melanoma	0.00244	0.00374	CcSEcCtD
Degarelix—Alopecia—Dactinomycin—melanoma	0.00244	0.00372	CcSEcCtD
Degarelix—Eye disorder—Carmustine—melanoma	0.00241	0.00369	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—TAS2R60—melanoma	0.00241	0.00696	CbGpPWpGaD
Degarelix—Erythema—Dactinomycin—melanoma	0.0024	0.00367	CcSEcCtD
Degarelix—Ill-defined disorder—Bleomycin—melanoma	0.00239	0.00365	CcSEcCtD
Degarelix—Anaemia—Bleomycin—melanoma	0.00238	0.00364	CcSEcCtD
Degarelix—Diarrhoea—Vemurafenib—melanoma	0.00237	0.00363	CcSEcCtD
Degarelix—Eye disorder—Temozolomide—melanoma	0.00233	0.00356	CcSEcCtD
Degarelix—Malaise—Bleomycin—melanoma	0.00232	0.00355	CcSEcCtD
Degarelix—Cardiac disorder—Temozolomide—melanoma	0.00231	0.00354	CcSEcCtD
Degarelix—Arrhythmia—Carmustine—melanoma	0.0023	0.00352	CcSEcCtD
Degarelix—Dizziness—Vemurafenib—melanoma	0.00229	0.0035	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—F2R—melanoma	0.00228	0.0066	CbGpPWpGaD
Degarelix—Alopecia—Carmustine—melanoma	0.00228	0.00349	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—EDN1—melanoma	0.00227	0.00657	CbGpPWpGaD
Degarelix—Angiopathy—Temozolomide—melanoma	0.00226	0.00346	CcSEcCtD
Degarelix—Mental disorder—Carmustine—melanoma	0.00226	0.00346	CcSEcCtD
Degarelix—Immune system disorder—Temozolomide—melanoma	0.00225	0.00344	CcSEcCtD
Degarelix—Mediastinal disorder—Temozolomide—melanoma	0.00225	0.00343	CcSEcCtD
Degarelix—Erythema—Carmustine—melanoma	0.00225	0.00343	CcSEcCtD
Degarelix—Malnutrition—Carmustine—melanoma	0.00225	0.00343	CcSEcCtD
Degarelix—Chills—Temozolomide—melanoma	0.00224	0.00342	CcSEcCtD
Degarelix—Ill-defined disorder—Dactinomycin—melanoma	0.00223	0.0034	CcSEcCtD
Degarelix—Anaemia—Dactinomycin—melanoma	0.00222	0.00339	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDNRB—melanoma	0.00221	0.00639	CbGpPWpGaD
Degarelix—Vomiting—Vemurafenib—melanoma	0.0022	0.00337	CcSEcCtD
Degarelix—Alopecia—Temozolomide—melanoma	0.0022	0.00337	CcSEcCtD
Degarelix—Rash—Vemurafenib—melanoma	0.00219	0.00334	CcSEcCtD
Degarelix—Mental disorder—Temozolomide—melanoma	0.00218	0.00334	CcSEcCtD
Degarelix—Dermatitis—Vemurafenib—melanoma	0.00218	0.00334	CcSEcCtD
Degarelix—Back pain—Carmustine—melanoma	0.00217	0.00332	CcSEcCtD
Degarelix—Headache—Vemurafenib—melanoma	0.00217	0.00332	CcSEcCtD
Degarelix—Erythema—Temozolomide—melanoma	0.00217	0.00332	CcSEcCtD
Degarelix—Malnutrition—Temozolomide—melanoma	0.00217	0.00332	CcSEcCtD
Degarelix—Breast disorder—Docetaxel—melanoma	0.00217	0.00331	CcSEcCtD
Degarelix—Discomfort—Bleomycin—melanoma	0.00216	0.00331	CcSEcCtD
Degarelix—Malaise—Dactinomycin—melanoma	0.00216	0.00331	CcSEcCtD
Degarelix—Vision blurred—Carmustine—melanoma	0.00212	0.00324	CcSEcCtD
Degarelix—Anaphylactic shock—Bleomycin—melanoma	0.0021	0.00321	CcSEcCtD
Degarelix—Back pain—Temozolomide—melanoma	0.0021	0.00321	CcSEcCtD
Degarelix—Anaemia—Carmustine—melanoma	0.00208	0.00317	CcSEcCtD
Degarelix—Nausea—Vemurafenib—melanoma	0.00206	0.00315	CcSEcCtD
Degarelix—Vision blurred—Temozolomide—melanoma	0.00205	0.00313	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—CXCR2—melanoma	0.00204	0.00591	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—melanoma	0.00203	0.00587	CbGpPWpGaD
Degarelix—Discomfort—Dactinomycin—melanoma	0.00202	0.00309	CcSEcCtD
Degarelix—Ill-defined disorder—Temozolomide—melanoma	0.00201	0.00308	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—CXCL1—melanoma	0.00201	0.00581	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PLCB4—melanoma	0.00201	0.00581	CbGpPWpGaD
Degarelix—Anaemia—Temozolomide—melanoma	0.00201	0.00307	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—WNT5A—melanoma	0.00198	0.00572	CbGpPWpGaD
Degarelix—Hypotension—Bleomycin—melanoma	0.00196	0.003	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR4—melanoma	0.00196	0.00567	CbGpPWpGaD
Degarelix—Malaise—Temozolomide—melanoma	0.00196	0.00299	CcSEcCtD
Degarelix—Hypertension—Carmustine—melanoma	0.00194	0.00296	CcSEcCtD
Degarelix—Palpitations—Temozolomide—melanoma	0.00192	0.00293	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Bleomycin—melanoma	0.00191	0.00292	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCA—melanoma	0.0019	0.0055	CbGpPWpGaD
Degarelix—Weight increased—Docetaxel—melanoma	0.00189	0.00288	CcSEcCtD
Degarelix—Weight decreased—Docetaxel—melanoma	0.00187	0.00286	CcSEcCtD
Degarelix—Hypertension—Temozolomide—melanoma	0.00187	0.00286	CcSEcCtD
Degarelix—Dyspnoea—Bleomycin—melanoma	0.00187	0.00286	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K2—melanoma	0.00186	0.00538	CbGpPWpGaD
Degarelix—Arthralgia—Temozolomide—melanoma	0.00185	0.00282	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00184	0.00281	CcSEcCtD
Degarelix—Discomfort—Temozolomide—melanoma	0.00183	0.00279	CcSEcCtD
Degarelix—Decreased appetite—Bleomycin—melanoma	0.00183	0.00279	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PLCB4—melanoma	0.00182	0.00528	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CXCL1—melanoma	0.00182	0.00528	CbGpPWpGaD
Degarelix—Acute coronary syndrome—Docetaxel—melanoma	0.00182	0.00278	CcSEcCtD
Degarelix—Renal failure—Docetaxel—melanoma	0.00182	0.00278	CcSEcCtD
Degarelix—Myocardial infarction—Docetaxel—melanoma	0.00181	0.00277	CcSEcCtD
Degarelix—Dry mouth—Temozolomide—melanoma	0.00181	0.00276	CcSEcCtD
Degarelix—Pain—Bleomycin—melanoma	0.0018	0.00274	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00178	0.00273	CcSEcCtD
Degarelix—Anaphylactic shock—Temozolomide—melanoma	0.00177	0.00271	CcSEcCtD
Degarelix—Hepatobiliary disease—Docetaxel—melanoma	0.00175	0.00267	CcSEcCtD
Degarelix—Nervous system disorder—Temozolomide—melanoma	0.00174	0.00266	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—F2R—melanoma	0.00174	0.00502	CbGpPWpGaD
Degarelix—Feeling abnormal—Bleomycin—melanoma	0.00173	0.00265	CcSEcCtD
Degarelix—Skin disorder—Temozolomide—melanoma	0.00172	0.00263	CcSEcCtD
Degarelix—Hypotension—Carmustine—melanoma	0.00171	0.00262	CcSEcCtD
Degarelix—Hyperhidrosis—Temozolomide—melanoma	0.00171	0.00262	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—F2RL1—melanoma	0.00171	0.00494	CbGpPWpGaD
Degarelix—Decreased appetite—Dactinomycin—melanoma	0.0017	0.0026	CcSEcCtD
Degarelix—Fatigue—Dactinomycin—melanoma	0.00169	0.00258	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—EDNRB—melanoma	0.00168	0.00486	CbGpPWpGaD
Degarelix—Pain—Dactinomycin—melanoma	0.00167	0.00256	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—DRAP1—melanoma	0.00167	0.00484	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MYO7A—melanoma	0.00167	0.00484	CbGpPWpGaD
Degarelix—Musculoskeletal discomfort—Carmustine—melanoma	0.00167	0.00255	CcSEcCtD
Degarelix—Urticaria—Bleomycin—melanoma	0.00167	0.00255	CcSEcCtD
Degarelix—Body temperature increased—Bleomycin—melanoma	0.00166	0.00254	CcSEcCtD
Degarelix—Insomnia—Carmustine—melanoma	0.00166	0.00253	CcSEcCtD
Degarelix—Hypoaesthesia—Docetaxel—melanoma	0.00165	0.00252	CcSEcCtD
Degarelix—Urinary tract disorder—Docetaxel—melanoma	0.00164	0.0025	CcSEcCtD
Degarelix—Dyspnoea—Carmustine—melanoma	0.00163	0.0025	CcSEcCtD
Degarelix—Oedema peripheral—Docetaxel—melanoma	0.00163	0.0025	CcSEcCtD
Degarelix—Urethral disorder—Docetaxel—melanoma	0.00163	0.00248	CcSEcCtD
Degarelix—Feeling abnormal—Dactinomycin—melanoma	0.00161	0.00247	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Temozolomide—melanoma	0.00161	0.00247	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—GRM3—melanoma	0.00161	0.00465	CbGpPWpGaD
Degarelix—Insomnia—Temozolomide—melanoma	0.0016	0.00245	CcSEcCtD
Degarelix—Gastrointestinal pain—Dactinomycin—melanoma	0.0016	0.00245	CcSEcCtD
Degarelix—Decreased appetite—Carmustine—melanoma	0.00159	0.00244	CcSEcCtD
Degarelix—Gastrointestinal disorder—Carmustine—melanoma	0.00158	0.00242	CcSEcCtD
Degarelix—Dyspnoea—Temozolomide—melanoma	0.00158	0.00241	CcSEcCtD
Degarelix—Constipation—Carmustine—melanoma	0.00157	0.0024	CcSEcCtD
Degarelix—Pain—Carmustine—melanoma	0.00157	0.0024	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—F2RL1—melanoma	0.00155	0.00449	CbGpPWpGaD
Degarelix—Eye disorder—Docetaxel—melanoma	0.00155	0.00237	CcSEcCtD
Degarelix—Body temperature increased—Dactinomycin—melanoma	0.00155	0.00237	CcSEcCtD
Degarelix—Abdominal pain—Dactinomycin—melanoma	0.00155	0.00237	CcSEcCtD
Degarelix—Hypersensitivity—Bleomycin—melanoma	0.00155	0.00236	CcSEcCtD
Degarelix—Decreased appetite—Temozolomide—melanoma	0.00154	0.00235	CcSEcCtD
Degarelix—Cardiac disorder—Docetaxel—melanoma	0.00154	0.00235	CcSEcCtD
Degarelix—Gastrointestinal disorder—Temozolomide—melanoma	0.00153	0.00234	CcSEcCtD
Degarelix—Fatigue—Temozolomide—melanoma	0.00153	0.00233	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—KISS1—melanoma	0.00152	0.0044	CbGpPWpGaD
Degarelix—Constipation—Temozolomide—melanoma	0.00151	0.00232	CcSEcCtD
Degarelix—Pain—Temozolomide—melanoma	0.00151	0.00232	CcSEcCtD
Degarelix—Feeling abnormal—Carmustine—melanoma	0.00151	0.00231	CcSEcCtD
Degarelix—Asthenia—Bleomycin—melanoma	0.00151	0.0023	CcSEcCtD
Degarelix—Angiopathy—Docetaxel—melanoma	0.0015	0.0023	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDN1—melanoma	0.0015	0.00435	CbGpPWpGaD
Degarelix—Gastrointestinal pain—Carmustine—melanoma	0.0015	0.00229	CcSEcCtD
Degarelix—Immune system disorder—Docetaxel—melanoma	0.0015	0.00229	CcSEcCtD
Degarelix—Mediastinal disorder—Docetaxel—melanoma	0.00149	0.00228	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—CXCR4—melanoma	0.00149	0.00432	CbGpPWpGaD
Degarelix—Chills—Docetaxel—melanoma	0.00149	0.00227	CcSEcCtD
Degarelix—Pruritus—Bleomycin—melanoma	0.00149	0.00227	CcSEcCtD
Degarelix—Arrhythmia—Docetaxel—melanoma	0.00148	0.00226	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—CXCR1—melanoma	0.00148	0.00427	CbGpPWpGaD
Degarelix—Alopecia—Docetaxel—melanoma	0.00147	0.00224	CcSEcCtD
Degarelix—Feeling abnormal—Temozolomide—melanoma	0.00146	0.00223	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—GRM3—melanoma	0.00146	0.00422	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—MC1R—melanoma	0.00145	0.0042	CbGpPWpGaD
Degarelix—Mental disorder—Docetaxel—melanoma	0.00145	0.00222	CcSEcCtD
Degarelix—Body temperature increased—Carmustine—melanoma	0.00145	0.00221	CcSEcCtD
Degarelix—Abdominal pain—Carmustine—melanoma	0.00145	0.00221	CcSEcCtD
Degarelix—Gastrointestinal pain—Temozolomide—melanoma	0.00145	0.00221	CcSEcCtD
Degarelix—Erythema—Docetaxel—melanoma	0.00144	0.00221	CcSEcCtD
Degarelix—Malnutrition—Docetaxel—melanoma	0.00144	0.00221	CcSEcCtD
Degarelix—Hypersensitivity—Dactinomycin—melanoma	0.00144	0.00221	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—TAS2R60—melanoma	0.00142	0.00411	CbGpPWpGaD
Degarelix—Urticaria—Temozolomide—melanoma	0.00141	0.00215	CcSEcCtD
Degarelix—Asthenia—Dactinomycin—melanoma	0.00141	0.00215	CcSEcCtD
Degarelix—Abdominal pain—Temozolomide—melanoma	0.0014	0.00214	CcSEcCtD
Degarelix—Body temperature increased—Temozolomide—melanoma	0.0014	0.00214	CcSEcCtD
Degarelix—Back pain—Docetaxel—melanoma	0.0014	0.00213	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—GRM1—melanoma	0.00139	0.00403	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CCR7—melanoma	0.00139	0.00403	CbGpPWpGaD
Degarelix—Muscle spasms—Docetaxel—melanoma	0.00139	0.00212	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—KISS1—melanoma	0.00138	0.004	CbGpPWpGaD
Degarelix—Hypersensitivity—Carmustine—melanoma	0.00135	0.00206	CcSEcCtD
Degarelix—Diarrhoea—Dactinomycin—melanoma	0.00134	0.00205	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—CXCR1—melanoma	0.00134	0.00387	CbGpPWpGaD
Degarelix—Vomiting—Bleomycin—melanoma	0.00134	0.00204	CcSEcCtD
Degarelix—Anaemia—Docetaxel—melanoma	0.00133	0.00204	CcSEcCtD
Degarelix—Rash—Bleomycin—melanoma	0.00132	0.00202	CcSEcCtD
Degarelix—Dermatitis—Bleomycin—melanoma	0.00132	0.00202	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—MC1R—melanoma	0.00132	0.00382	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—melanoma	0.00132	0.00381	CbGpPWpGaD
Degarelix—Asthenia—Carmustine—melanoma	0.00132	0.00201	CcSEcCtD
Degarelix—Hypersensitivity—Temozolomide—melanoma	0.00131	0.00199	CcSEcCtD
Degarelix—Palpitations—Docetaxel—melanoma	0.00128	0.00195	CcSEcCtD
Degarelix—Asthenia—Temozolomide—melanoma	0.00127	0.00194	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—RHOB—melanoma	0.00127	0.00367	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GRM1—melanoma	0.00126	0.00366	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CCR7—melanoma	0.00126	0.00366	CbGpPWpGaD
Degarelix—Diarrhoea—Carmustine—melanoma	0.00125	0.00192	CcSEcCtD
Degarelix—Pruritus—Temozolomide—melanoma	0.00125	0.00192	CcSEcCtD
Degarelix—Nausea—Bleomycin—melanoma	0.00125	0.00191	CcSEcCtD
Degarelix—Hypertension—Docetaxel—melanoma	0.00125	0.0019	CcSEcCtD
Degarelix—Vomiting—Dactinomycin—melanoma	0.00125	0.0019	CcSEcCtD
Degarelix—Rash—Dactinomycin—melanoma	0.00123	0.00189	CcSEcCtD
Degarelix—Arthralgia—Docetaxel—melanoma	0.00123	0.00188	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00122	0.00187	CcSEcCtD
Degarelix—Dizziness—Carmustine—melanoma	0.00121	0.00185	CcSEcCtD
Degarelix—Diarrhoea—Temozolomide—melanoma	0.00121	0.00185	CcSEcCtD
Degarelix—Dry mouth—Docetaxel—melanoma	0.0012	0.00184	CcSEcCtD
Degarelix—Anaphylactic shock—Docetaxel—melanoma	0.00118	0.0018	CcSEcCtD
Degarelix—Dizziness—Temozolomide—melanoma	0.00117	0.00179	CcSEcCtD
Degarelix—Vomiting—Carmustine—melanoma	0.00117	0.00178	CcSEcCtD
Degarelix—Nausea—Dactinomycin—melanoma	0.00116	0.00178	CcSEcCtD
Degarelix—Rash—Carmustine—melanoma	0.00116	0.00177	CcSEcCtD
Degarelix—Nervous system disorder—Docetaxel—melanoma	0.00116	0.00177	CcSEcCtD
Degarelix—Dermatitis—Carmustine—melanoma	0.00115	0.00177	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—CXCR2—melanoma	0.00115	0.00334	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—RHOB—melanoma	0.00115	0.00333	CbGpPWpGaD
Degarelix—Headache—Carmustine—melanoma	0.00115	0.00176	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—EDN1—melanoma	0.00114	0.00331	CbGpPWpGaD
Degarelix—Skin disorder—Docetaxel—melanoma	0.00114	0.00175	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—RAC2—melanoma	0.00114	0.00328	CbGpPWpGaD
Degarelix—Vomiting—Temozolomide—melanoma	0.00113	0.00172	CcSEcCtD
Degarelix—Rash—Temozolomide—melanoma	0.00112	0.00171	CcSEcCtD
Degarelix—Dermatitis—Temozolomide—melanoma	0.00112	0.00171	CcSEcCtD
Degarelix—Headache—Temozolomide—melanoma	0.00111	0.0017	CcSEcCtD
Degarelix—Hypotension—Docetaxel—melanoma	0.0011	0.00168	CcSEcCtD
Degarelix—Nausea—Carmustine—melanoma	0.00109	0.00166	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PLCB4—melanoma	0.00108	0.00312	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCL1—melanoma	0.00108	0.00312	CbGpPWpGaD
Degarelix—Musculoskeletal discomfort—Docetaxel—melanoma	0.00107	0.00164	CcSEcCtD
Degarelix—Insomnia—Docetaxel—melanoma	0.00107	0.00163	CcSEcCtD
Degarelix—Nausea—Temozolomide—melanoma	0.00105	0.00161	CcSEcCtD
Degarelix—Dyspnoea—Docetaxel—melanoma	0.00105	0.00161	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—CXCR2—melanoma	0.00105	0.00303	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—RAC2—melanoma	0.00103	0.00298	CbGpPWpGaD
Degarelix—Decreased appetite—Docetaxel—melanoma	0.00102	0.00157	CcSEcCtD
Degarelix—Gastrointestinal disorder—Docetaxel—melanoma	0.00102	0.00155	CcSEcCtD
Degarelix—Fatigue—Docetaxel—melanoma	0.00102	0.00155	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—WNT5A—melanoma	0.00102	0.00294	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TRRAP—melanoma	0.00101	0.00293	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CUL3—melanoma	0.00101	0.00293	CbGpPWpGaD
Degarelix—Pain—Docetaxel—melanoma	0.00101	0.00154	CcSEcCtD
Degarelix—Constipation—Docetaxel—melanoma	0.00101	0.00154	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—AKR1B10—melanoma	0.000986	0.00285	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—F2R—melanoma	0.000981	0.00284	CbGpPWpGaD
Degarelix—Feeling abnormal—Docetaxel—melanoma	0.000971	0.00148	CcSEcCtD
Degarelix—Gastrointestinal pain—Docetaxel—melanoma	0.000963	0.00147	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—EDNRB—melanoma	0.00095	0.00275	CbGpPWpGaD
Degarelix—Body temperature increased—Docetaxel—melanoma	0.000931	0.00142	CcSEcCtD
Degarelix—Abdominal pain—Docetaxel—melanoma	0.000931	0.00142	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—F2RL1—melanoma	0.000917	0.00265	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—GNA11—melanoma	0.000898	0.0026	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—GAB2—melanoma	0.000898	0.0026	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—F2R—melanoma	0.000891	0.00258	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—melanoma	0.00088	0.00255	CbGpPWpGaD
Degarelix—Hypersensitivity—Docetaxel—melanoma	0.000868	0.00133	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—EDNRB—melanoma	0.000863	0.0025	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GRM3—melanoma	0.000862	0.00249	CbGpPWpGaD
Degarelix—Asthenia—Docetaxel—melanoma	0.000845	0.00129	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—CXCR4—melanoma	0.000844	0.00244	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—melanoma	0.000843	0.00244	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—GNAQ—melanoma	0.000834	0.00241	CbGpPWpGaD
Degarelix—Pruritus—Docetaxel—melanoma	0.000833	0.00127	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—KISS1—melanoma	0.000817	0.00236	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GAB2—melanoma	0.000815	0.00236	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GNA11—melanoma	0.000815	0.00236	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.000813	0.00235	CbGpPWpGaD
Degarelix—Diarrhoea—Docetaxel—melanoma	0.000806	0.00123	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—melanoma	0.000802	0.00232	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—melanoma	0.000802	0.00232	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SKI—melanoma	0.000791	0.00229	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCR1—melanoma	0.000791	0.00229	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MC1R—melanoma	0.000779	0.00225	CbGpPWpGaD
Degarelix—Dizziness—Docetaxel—melanoma	0.000779	0.00119	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—PIK3CA—melanoma	0.000778	0.00225	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—AKT3—melanoma	0.00077	0.00223	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CXCR4—melanoma	0.000766	0.00222	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GNAQ—melanoma	0.000758	0.00219	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—melanoma	0.000758	0.00219	CbGpPWpGaD
Degarelix—Vomiting—Docetaxel—melanoma	0.000749	0.00114	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—GRM1—melanoma	0.000747	0.00216	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCR7—melanoma	0.000747	0.00216	CbGpPWpGaD
Degarelix—Rash—Docetaxel—melanoma	0.000743	0.00114	CcSEcCtD
Degarelix—Dermatitis—Docetaxel—melanoma	0.000742	0.00113	CcSEcCtD
Degarelix—Headache—Docetaxel—melanoma	0.000738	0.00113	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—SUFU—melanoma	0.000728	0.00211	CbGpPWpGaD
Degarelix—Nausea—Docetaxel—melanoma	0.0007	0.00107	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—AKT3—melanoma	0.000699	0.00202	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—melanoma	0.000696	0.00201	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—BCL2L11—melanoma	0.00068	0.00197	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RHOB—melanoma	0.00068	0.00197	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HDAC6—melanoma	0.000653	0.00189	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—EDN1—melanoma	0.000647	0.00187	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—melanoma	0.000644	0.00186	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CSF2—melanoma	0.000632	0.00183	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCR2—melanoma	0.000619	0.00179	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCL8—melanoma	0.000619	0.00179	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—melanoma	0.000616	0.00178	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RAC2—melanoma	0.000609	0.00176	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PRKCA—melanoma	0.000606	0.00175	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—WNT5A—melanoma	0.0006	0.00173	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VEGFC—melanoma	0.0006	0.00173	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—EDN1—melanoma	0.000588	0.0017	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CSF2—melanoma	0.000574	0.00166	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—RAC1—melanoma	0.000562	0.00163	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PRKCA—melanoma	0.000551	0.00159	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—MAP2K2—melanoma	0.000538	0.00156	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—F2R—melanoma	0.000526	0.00152	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—RAC1—melanoma	0.00051	0.00148	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EDNRB—melanoma	0.00051	0.00147	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PTK2B—melanoma	0.000495	0.00143	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GAB2—melanoma	0.000482	0.00139	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GNA11—melanoma	0.000482	0.00139	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FLT1—melanoma	0.000479	0.00139	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CG—melanoma	0.000475	0.00137	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCR4—melanoma	0.000453	0.00131	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FOXO4—melanoma	0.000453	0.00131	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HDAC2—melanoma	0.000453	0.00131	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GNAQ—melanoma	0.000448	0.00129	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CG—melanoma	0.000431	0.00125	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SYK—melanoma	0.000421	0.00122	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CD—melanoma	0.000417	0.00121	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ITGAV—melanoma	0.000413	0.00119	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AKT3—melanoma	0.000413	0.00119	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NGFR—melanoma	0.000413	0.00119	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SOCS1—melanoma	0.000383	0.00111	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—MAP2K1—melanoma	0.000382	0.0011	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—S100B—melanoma	0.000382	0.0011	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CD—melanoma	0.000379	0.0011	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ERBB4—melanoma	0.000365	0.00106	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CB—melanoma	0.000364	0.00105	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CDKN2B—melanoma	0.000362	0.00105	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CD86—melanoma	0.00035	0.00101	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CXCL8—melanoma	0.00035	0.00101	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EDN1—melanoma	0.000347	0.001	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CSF2—melanoma	0.000339	0.000981	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FGF1—melanoma	0.000339	0.000981	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—IL2—melanoma	0.000334	0.000967	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—E2F1—melanoma	0.000332	0.00096	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CB—melanoma	0.00033	0.000956	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PDGFRA—melanoma	0.000329	0.00095	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ITGB3—melanoma	0.000325	0.000941	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PRKCA—melanoma	0.000325	0.000941	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SPP1—melanoma	0.000319	0.000923	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAP2K2—melanoma	0.000318	0.00092	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CXCL8—melanoma	0.000318	0.000918	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IL2—melanoma	0.000303	0.000878	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TERT—melanoma	0.000302	0.000875	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RAC1—melanoma	0.000302	0.000872	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HIF1A—melanoma	0.000289	0.000836	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KDR—melanoma	0.000277	0.0008	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FN1—melanoma	0.000266	0.00077	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NOTCH1—melanoma	0.000261	0.000753	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CD80—melanoma	0.000255	0.000738	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—APC—melanoma	0.000255	0.000737	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CG—melanoma	0.000255	0.000737	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KIT—melanoma	0.000255	0.000737	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—NRAS—melanoma	0.000255	0.000737	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EGF—melanoma	0.000252	0.000728	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—MAPK3—melanoma	0.000244	0.000706	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—BRAF—melanoma	0.000239	0.000693	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IGF1—melanoma	0.000233	0.000675	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—MAPK1—melanoma	0.000232	0.000671	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—EGFR—melanoma	0.000232	0.000671	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAP2K1—melanoma	0.000225	0.000652	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CD—melanoma	0.000224	0.000648	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CA—melanoma	0.000222	0.000642	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—KRAS—melanoma	0.000219	0.000634	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FGF2—melanoma	0.000214	0.00062	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CA—melanoma	0.000201	0.000583	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MDM2—melanoma	0.000201	0.00058	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ERBB2—melanoma	0.000198	0.000572	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CB—melanoma	0.000195	0.000565	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCL8—melanoma	0.000188	0.000543	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—HRAS—melanoma	0.000186	0.000539	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CDKN1B—melanoma	0.000183	0.00053	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—AKT1—melanoma	0.000181	0.000524	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CASP3—melanoma	0.00018	0.000519	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL2—melanoma	0.000179	0.000519	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IL6—melanoma	0.000178	0.000516	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCND1—melanoma	0.000175	0.000505	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CTNNB1—melanoma	0.000173	0.000501	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MMP9—melanoma	0.00017	0.000491	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CDKN1A—melanoma	0.000169	0.000489	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PTEN—melanoma	0.000169	0.000488	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NFKB1—melanoma	0.000168	0.000486	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AKT1—melanoma	0.000165	0.000476	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VEGFA—melanoma	0.000152	0.000441	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—STAT3—melanoma	0.000151	0.000436	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NRAS—melanoma	0.00015	0.000435	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAPK3—melanoma	0.000144	0.000417	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MYC—melanoma	0.00014	0.000405	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAPK1—melanoma	0.000137	0.000397	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EGFR—melanoma	0.000137	0.000397	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KRAS—melanoma	0.00013	0.000375	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CA—melanoma	0.000119	0.000344	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TP53—melanoma	0.000115	0.000333	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HRAS—melanoma	0.00011	0.000318	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL6—melanoma	0.000105	0.000305	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AKT1—melanoma	9.72e-05	0.000281	CbGpPWpGaD
